REJUVENON'S GHRELIN MIMETIC RECEIVES FAST-TRACK STATUS

Rejuvenon has received word from the FDA that its investigational compound, RC-1291, a small-molecule ghrelin mimetic, has been granted fast-track status.

RC-1291 is intended for the treatment of cachexia (loss of body weight) and anorexia (loss of appetite) in cancer patients. This syndrome frequently accompanies malignant disease states and often results in the death of the patient.

To date, there are no effective treatments approved for this indication, Rejuvenon said.